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MicroRNAs (miRNAs) are small non-coding RNAs that function as endogenous silencers
of numerous target genes. Hundreds of miRNAs have been identiﬁed in the human
genome. miRNAs are expressed in a tissue-speciﬁc manner and play important roles in
cell proliferation, apoptosis, and differentiation. Aberrant expression of miRNAs may also
contribute to the development and progression of human hepatobiliary and pancreatic can-
cers. Recent studies have shown that some miRNAs play roles as tumor suppressors or
oncogenes in hepatobiliary and pancreatic cancers. miR-122, let-7 family, and miR-101 are
down-regulated in hepatocellular carcinoma (HCC), suggesting that it is a potential tumor
suppressor of HCC. miR-221 and miR-222 are up-regulated in HCC and may act as onco-
genic miRNAs in hepatocarcinogenesis. miRNA expression proﬁling may be a powerful
clinical tool for diagnosis and regulation of miRNA expression could be a novel therapeutic
strategy for hepatobiliary and pancreatic cancers. In this review, we summarize current
knowledge about the roles of important tumor suppressor microRNAs and oncogenic
microRNAs in hepatobiliary and pancreatic cancers.
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THE BIOGENESIS OF microRNAs
MicroRNAs (miRNAs) are∼22 nucleotide (nt) non-coding RNAs
that can post-transcriptionally downregulate the expression of
various target genes. Currently,∼1400 human miRNAs have been
identiﬁed in the human genome, and each miRNA potentially
controls hundreds of target genes. miRNAs are expressed in a
tissue-speciﬁc manner and play important roles in cell prolifera-
tion, apoptosis, and differentiation. Moreover, recent studies have
shown a link between aberrant expression of miRNAs and the
development of cancer (Saito et al., 2009a; Calin and Croce, 2007;
Cho, 2007).
In animals, miRNA genes are generally transcribed by RNA
polymerase II (pol II) to form primary transcripts (pri-miRNAs).
Pol II transcribedpri-miRNAs are cappedwith 7-methylguanosine
and polyadenylated. The nuclear RNase III enzyme Drosha and
its co-factor Pasha (also known as DGCR8) process pri-miRNAs
into ∼60 nt precursor miRNAs (pre-miRNAs) which form an
imperfect stem–loop structure. Pre-miRNAs are transported into
the cytoplasm by the RAN GTP-dependent transporter exportin
5 and are subsequently cleaved by the cytoplasmic RNase III
enzyme Dicer into mature miRNAs which are then loaded into
the RNA-induced silencing complex (RISC). The miRNA/RISC
complex downregulates speciﬁc gene products by translational
repression via binding to partially complementary sequences
in the 3′ untranslated regions (3′-UTRs) of the target mRNAs
Abbreviations: 5-Aza-CdR, 5-aza-2′-deoxycytidine; HCC, hepatocellular carci-
noma; HCV, hepatitis C virus; HDAC, histone deacetylase; LOH, loss of heterozy-
gosity; miRNA, microRNA; PBA, 4-phenylbutyric acid; PDAC, pancreatic ductal
adenocarcinoma.
or by directing mRNA degradation via binding to perfectly
complementary sequences.
Identiﬁcation of miRNA target genes is critical to determin-
ing the miRNA functions. There are several databases of human
miRNA target predictions using different algorithms such as
microRNA.org1 miRBase2 PicTar3 and TargetScan4 It is gener-
ally believed that conserved perfect 6–8 base-pair (bp) matches
between the 5′ end of the mature miRNA and the 3′ UTR of
the predicted target mRNA (called “seed” matches) are the most
reliable way of determining miRNA targets. Experimental conﬁr-
mation using protein expression and luciferase reporter assays for
the miRNA targets is necessary to accurately identify the target
genes of miRNAs.
REGULATORY MECHANISMS OF miRNA EXPRESSION
Since miRNAs can have large-scale effects through regulation of a
variety of genes during mammalian development and carcinogen-
esis, an understanding of the regulatory mechanisms controlling
miRNA expression, which is quite limited at present, is impor-
tant. There are several reports of transcription factors binding
to the promoter regions of speciﬁc miRNA genes and activating
the transcription of pri-miRNAs, resulting in increased expression
of mature miRNAs. c-Myc binds to the regulatory region of the
miR-17-92 cluster and increased expression of c-Myc leads to the
activation of the miRNAs in the cluster (O’Donnell et al., 2005).
1http://www.microrna.org/microrna/home.do,
2http://www.mirbase.org,
3http://pictar.mdc-berlin.de,
4http://www.targetscan.org.
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The location of miRNA genes is also an important factor in the
regulation of miRNA expression. Many miRNAs are located in
cancer-associated genomic regions that are frequently involved in
chromosomal abnormalities, such as loss of heterozygosity (LOH),
ampliﬁcation, and breakpoints (Calin et al., 2004). Chromoso-
mal abnormalities during carcinogenesis could lead to widespread
differential expressions of miRNAs in human cancer cells.
Epigenetic alterations such as DNA methylation and histone
modiﬁcation play critical roles in chromatin remodeling and reg-
ulation of gene expression in mammalian development and in
human diseases. Many miRNAs are expressed in a tissue and
tumor speciﬁc manner, implying that some miRNAs are subject to
epigenetic control. We have recently shown that miR-127, which
is embedded in a CpG island, is strongly induced by the treat-
ment with the DNA demethylating agent 5-aza-2′-deoxycytidine
(5-Aza-CdR) and the histone deacetylase (HDAC) inhibitor 4-
phenylbutyric acid (PBA), indicating that some miRNA genes are
controlled by epigenetic alterations in their promoter regions and
can be activated by chromatin modifying drugs (Saito et al., 2006,
2009b).
MicroRNAs expression proﬁles can be used to classify the
developmental lineages and differentiation stages of tumors. Inter-
estingly, miRNA expression proﬁles are more accurate for tumor
classiﬁcation than conventional mRNA proﬁling (Lu et al., 2005).
Furthermore, recent studies have demonstrated the association of
miRNA expression signatures with prognostic and disease pro-
gression factors in human malignancies (Calin and Croce, 2006).
These ﬁndings indicate that miRNA expression proﬁle might
be a powerful clinical tool for the diagnosis and prognosis of
malignancies.
IMPORTANT TUMOR SUPPRESSOR AND ONCOGENIC
miRNAs IN HCC
Hepatocellular carcinoma (HCC) is the most common type of
liver cancer. Most cases of HCC are secondary to either chronic
hepatitis or hepatic cirrhosis caused by a viral infection (hepatitis
B or C) or alcoholism. HCC accounts for 85–90% of all primary
liver cancers and is one of the most lethal cancers, and affects
many of the world’s population (Farazi and DePinho, 2006). The
lethality of liver cancer may cause from its resistance to existing
anticancer agents, a lack of biomarkers, and underlying liver dis-
ease that limits the use of chemotherapeutic drugs. In addition,
the molecular pathogenesis of HCC remains poorly understood.
As shown in Table 1, some miRNAs are overexpressed in HCCs,
indicating that they may have roles as oncogenes accelerating
the development of HCC. Some miRNAs are down-regulated in
HCCs, suggesting that they may act as tumor suppressors. miR-
NAs have critical roles in human hepatocarcinogenesis and that
aberrant expression of miRNAs may contribute to the initiation
and progression of HCC.
miR-122
miR-122 is speciﬁcally expressed and highly abundant in the
human liver. Recent studies have reported that miR-122 may
modulate and facilitate replication of hepatitis C virus (HCV),
suggesting thatmiR-122 could be a target for antiviral intervention
(Jopling et al., 2005; Li et al., 2011).
Table 1 | Putative tumor suppressor and oncogenic miRNAs in HCC.
miRNA Target genes References
PUTATIVETUMOR SUPPRESSOR miRNAs IN HCC
let-7 c-Myc, Bcl-xL, COL1A2 Ji et al. (2010)
Lan et al. (2011)
Shimizu et al. (2010)
miR-101 Mcl-1, FOS Su et al. (2009)
Li et al. (2009)
miR-122 Cyclin G1, SRF, Igf1R, Bcl-w, Gramantieri et al. (2007)
ADAM10, ADAM17 Lin et al. (2008)
Bai et al. (2009)
Fornari et al. (2009)
Tsai et al. (2009)
Ma et al. (2010)
PUTATIVE ONCOGENIC miRNAs IN HCC
miR-221/222 p27, p57, DDIT4, PTEN, le Sage et al. (2007)
Bmf, TIMP3, PPP2R2A Fornari et al. (2008)
Garofalo et al. (2009)
Gramantieri et al. (2009)
Pineau et al. (2010)
Wong et al. (2010)
miR-122 can modulate cyclin G1 expression in HCC-derived
cell lines and an inverse correlation between miR-122 and cyclin
G1 expression exists in HCCs, indicating that cyclin G1 is a target
of miR-122 (Gramantieri et al., 2007). In patients of HCC, lower
miR-122 levels were associated with a shorter time to recurrence,
whereas higher cyclinG1 expressionwas related to a lower survival,
suggesting that miR-122 might represent an effective molecular
target for HCC (Fornari et al., 2009).
miR-122 also modulates Bcl-w expression by directly targeting
binding site within the 3′-UTR. The cellular mRNA and protein
levels of Bcl-w were repressed by elevated levels of miR-122, which
subsequently led to reduction of cell viability and activation of
caspase-3, suggesting that Bcl-w is a direct target of miR-122 that
functions as an endogenous apoptosis enhancer in HCC cells (Lin
et al., 2008). Ma et al. (2010) generated a recombinant adenoviral
vector expressing miR-122 (Ad-miR-122). Infection of tumor cells
with Ad-miR-122 resulted in inhibition of growth of cancer cells.
This antitumor activity was related to the induction of apoptosis
and/or cell-cycle arrest in cancer cells. Infection with Ad-miR-122
resulted in decreased expression of Bcl-w and CCNG1 in can-
cer cells. Induction of miR-122 via adenoviral vector could be a
promising strategy for cancer treatment (Ma et al., 2010).
A distintegrin and metalloprotease family 10 (ADAM10),
serum response factor (SRF), and insulin-like growth factor 1
receptor (Igf1R) that promote tumorigenesis were validated as
targets of miR-122. ADAM10, SRF, and Igf1R were up-regulated
in primary human HCCs compared with the matching liver tissue,
suggesting that the loss of multifunctional miR-122 contributes to
the malignant phenotype of HCC cells (Bai et al., 2009).
Tsai et al. (2009) have shown that miR-122 is signiﬁ-
cantly down-regulated in HCCs with intrahepatic metastasis and
negatively regulates tumorigenesis. Restoration of miR-122 in
metastatic cells signiﬁcantly reduced in vitro migration, invasion,
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and anchorage-independent growth as well as in vivo tumorigen-
esis, angiogenesis, and intrahepatic metastasis. They have further
shown that one of the miR-122 targets, a disintegrin, and met-
alloprotease 17 (ADAM17) is involved in metastasis. Silencing of
ADAM17 resulted in a dramatic reduction of in vitro migration,
invasion, in vivo tumorigenesis, angiogenesis, and local invasion in
the livers of nude mice, indicating that miR-122 plays a role in the
intrahepatic metastasized HCC by the suppression of angiogenesis
via regulation of ADAM17 (Tsai et al., 2009).
These studies demonstrate that miR-122 is signiﬁcantly down-
regulated in HCCs and has multiple functions as a tumor suppres-
sor miRNA during hepatocarcinogenesis. miR-122 is a promising
target for HCC treatment as well as a diagnostic and prognostic
marker for the progression of HCC.miR-122 alone or in combina-
tion with anticancer drugs can be a promising therapeutic strategy
against HCC. Further studies are necessary to develop miRNA-
based therapy for HCC treatment. Since miR-122 can modulate
HCV replication, the status of HCV infection in HCC patients
should be detected carefully.
let-7 FAMILY
The let-7 family plays critical roles in tumorigenesis by function-
ing as potential tumor suppressor. The expression of let-7g was
markedly decreased in HCC cells. Proliferation of HCC cell line
was signiﬁcantly inhibited after the transfection of let-7g. Con-
currently, the mRNA and protein levels of c-Myc were found
signiﬁcantly decreased in HCC cells after transfection of let-7g.
let-7g may act as a tumor suppressor gene that inhibits HCC cell
proliferation by downregulating c-Myc (Lan et al., 2011). In addi-
tion, the level of let-7g was signiﬁcantly lower in metastatic HCCs
compared to metastasis-free HCCs. The low expression level of
let-7g in tumor was predictive of poor survival in HCC patients.
Type I collagen alpha2 (COL1A2) was validated as a direct tar-
get of let-7g, suggesting that let-7g may suppress HCC metastasis
through targeting COL1A2 (Ji et al., 2010).
Bcl-xL, an anti-apoptotic member of the Bcl-2 family, is iden-
tiﬁed as a target of let-7c and let-7g. Human HCC tissues with
low expression of let-7c displayed higher expression of Bcl-xL
protein than those with high expression of let-7c, suggesting that
low let-7 miRNA expression contributes to Bcl-xL overexpression.
let-7 miRNAs negatively regulate Bcl-xL expression and induce
apoptosis in human HCCs (Shimizu et al., 2010).
miR-101
Expression level of miR-101 was signiﬁcantly decreased in HCC
cell lines and HCC tissues compared with their non-tumor coun-
terparts. Ectopic expression of miR-101 dramatically suppressed
the ability of HCC cells to form colonies in vitro and to develop
tumors innudemice. In addition,miR-101 repressedMcl-1 expres-
sion as its target oncogene. These results indicate thatmiR-101may
exert its proapoptotic function via targetingMcl-1 (Su et al., 2009).
Li et al. (2009) have reported that miR-101 was signiﬁcantly down-
regulated in HCC tissues compared with the matching non-tumor
liver tissues. They also showed that miR-101 repressed the expres-
sion of v-fos FBJ murine osteosarcoma viral oncogene homolog
(FOS) oncogene, a key component of the activator protein-1
(AP-1) transcription factor. In in vitro invasion and migration
assays, enhanced miR-101 expression inhibited the invasion and
migration of cultured HCC cells. These ﬁndings suggest that miR-
101, which is aberrantly expressed in HCC, could repress the
expression of the FOS oncogene and may play an important role
as a tumor suppressor in HCC (Li et al., 2009).
miR-221 AND miR -222
miR-221 is overexpressed in human HCC as well as in other malig-
nancies. p27 Was identiﬁed as a target of miR-221 and miR-222
(le Sage et al., 2007). Fornari et al. (2008) have reported that
the cyclin-dependent kinase inhibitor p57 is also a direct tar-
get of miR-221. Indeed, downregulation of both p27 and p57
occurs in response to miR-221 transfection into HCC-derived
cells and a signiﬁcant upregulation of both p27 and p57 occurs in
response to anti-miR-221 transfection. They suggest that miR-221
has an oncogenic function in hepatocarcinogenesis by target-
ing p27 and p57, hence promoting proliferation by controlling
cell-cycle inhibitors (Fornari et al., 2008). miR-221 also targets
Bmf, a proapoptotic BH3-only protein, and inhibits apoptosis of
cells. miR-221 overexpression is associated with a more aggres-
sive phenotype of HCC (Gramantieri et al., 2009). In addition,
DNA damage-inducible transcript 4 (DDIT4), a modulator of
mTORpathway,was identiﬁed as a target of miR-221, indicating an
important contribution for miR-221 in hepatocarcinogenesis and
suggest a role for DDIT4 dysregulation in this process (Pineau
et al., 2010). Taken together, these ﬁndings indicate that miR-
221 simultaneously affects multiple pro-oncogenic pathways in
hepatocarcinogenesis.
Garofalo et al. (2009) have reported that miR-221 and miR-222
are overexpressed in HCC cells, as compared with normal liver
cells. They also show that miR-221 and miR-222 induce TRAIL
resistance and enhance cellular migration through the activation
of theAKT pathway and metallopeptidases by targeting PTEN and
TIMP3 tumor suppressors and that the MET oncogene is involved
in miR-221 and miR-222 activation through the c-Jun transcrip-
tion factor (Garofalo et al., 2009). Theprotein phosphatase 2A sub-
unit B (PPP2R2A) was identiﬁed as a target of miR-222. miR-222
overexpression is common in HCC and could confer metastatic
potentials in HCC cells, possibly through activatingAKT signaling
(Wong et al., 2010).
These studies strongly suggest that miR-221 and miR-222 are
oncogenic miRNAs that play critical roles in the initiation and
progression of human HCC. The use of synthetic inhibitors of
miR-221 and miR-222 may be a promising approach to HCC
treatment.
ABERRANT EXPRESSION OF miRNAs IN
CHOLANGIOCARCINOMA
Meng et al. (2006) have reported that miR-21, miR-141, and
miR-200b were highly overexpressed in malignant cholangiocytes.
They show thatmiR-21modulates gemcitabine-induced apoptosis
by phosphatase and tensin homolog deleted on chromosome 10
(PTEN)-dependent activation of PI 3-kinase signaling. This study
suggests that alterations inmiRNA expression contribute to tumor
growth and response to chemotherapy (Meng et al., 2006).
They also provide evidence that overexpression of IL-6 cause
upregulation of let-7a and reduction of miR-370 in malig-
nant human cholangiocytes. let-7a Contributes to the consti-
tutively increased phosphorylation of STAT-3 by a mechanism
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Table 2 | Putative tumor suppressor and oncogenic miRNAs in
pancreatic cancer.
miRNA Target genes References
PUTATIVETUMOR SUPPRESSOR miRNAs IN PANCREATIC CANCER
let-7 K-ras Torrisani et al. (2009)
miR-34a CDK6 Lodygin et al. (2008)
Chang et al. (2007)
PUTATIVE ONCOGENIC miRNA IN PANCREATIC CANCER
miR-155 TP53INP1 Gironella et al. (2007)
involving the neuroﬁbromatosis 2 (NF2) gene. The oncogene
mitogen-activated protein kinase kinase kinase 8 (MAP3K8) was
identiﬁed as a target of miR-370. Thus, let-7a modulates IL-6-
dependent STAT-3 survival signaling in malignant human cholan-
giocytes. In addition, IL-6 may contribute to tumor growth by
modulation of expression of selected miRNAs, such as miR-370.
Aberrantly expressed miRNA or their targets will provide mech-
anistic insight and therapeutic targets for cholangiocarcinoma
(Meng et al., 2007, 2008).
ABERRANT EXPRESSION OF miRNAs IN PANCREATIC
CANCER
Pancreatic ductal adenocarcinoma (PDAC) is still the fourth lead-
ing cause of cancer-related deaths in Western countries with
increasing incidence. Neither effective prognostic markers nor
therapies exist for PDAC.
As shown in Table 2, let-7 miRNA expression is remarkably
reduced in PDAC samples, as compared with adjacent tissue.
Restoring let-7 levels in cancer-derived cell lines strongly inhibits
cell proliferation, K-ras expression, and mitogen-activated protein
kinase activation (Torrisani et al., 2009). Chang et al. (2007) have
demonstrated that miR-34a is commonly deleted in human can-
cers and frequently absent in pancreatic cancer cells. miR-34a is
directly transactivated by the tumor suppressor p53. Expression of
miR-34a causes dramatic reprogramming of gene expression and
promotes apoptosis (Chang et al., 2007). miR-34a expression is
silenced in several types of cancer including pancreatic cancer due
to aberrant CpG methylation of its promoter. Re-expression of
miR-34a in pancreas carcinoma cell line induced senescence and
cell-cycle arrest at least in part by targeting CDK6. These results
show that miR-34a represents a tumor suppressor gene which is
inactivated by CpG methylation in pancreatic cancer (Lodygin
et al., 2008).
Gironella et al. (2007) have shown that oncogenic miRNA miR-
155 is overexpressed in PDAC cells and repress tumor protein
53-induced nuclear protein-1 (TP53INP1) as its target. TP53INP1
expression is dramatically reduced in PDAC and this decrease
occurs early during pancreatic cancer development (Gironella
et al., 2007; Table 2).
Besides miR-155, several miRNAs including miR-21, miR-221,
and miR-222 have been reported to be up-regulated in pancreatic
cancer, suggesting that they are potential oncogenic miRNAs (Lee
et al., 2007).
PERSPECTIVES AND CONCLUSION
The distinct connection between aberrant expressions of miRNAs
and the development of hepatobiliary and pancreatic cancers indi-
cates that miRNAs can be promising therapeutic targets. A recent
study have shown that chemically engineered oligonucleotides,
termed locked-nucleic-acid (LNA)-modiﬁedmiRNAs,were found
to be speciﬁc inhibitors of endogenous miRNAs in non-human
primates (Elmen et al., 2008). They could be used to silence onco-
genic miRNAs, such as miR-221 and miR-222 as a strategy for
HCC treatment. Regulation of miRNA expression by epigenetic
therapy using DNA methylation inhibitors and histone deacety-
lase (HDAC) inhibitors also has clinical promise for the treatment
of human malignancies. In addition, miRNA expression proﬁling
may be a powerful clinical tool for diagnosis of hepatobiliary and
pancreatic cancers.
Since the link between miRNAs and hepatobiliary and pan-
creatic cancers has only just begun to be understood and the
number of miRNA genes identiﬁed is increasing, there could be
a large number of therapeutic targets for HCCs, cholangiocarci-
nomas, and pancreatic cancers. Further studies are necessary to
investigate whether miRNA-mediated therapy can be an effective
approach for the chemopreventionof hepatobiliary andpancreatic
cancers.
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